New Medicare Codes for Tyenne Aim to Boost COVID-19 Treatment Access

LAKE ZURICH, IL – April 09, 2026 – As of this month, a significant administrative hurdle in the treatment of severe COVID-19 has been cleared. Healthcare providers administering Fresenius Kabi’s biosimilar drug, Tyenne® (tocilizumab-aazg), to eligible Medicare patients can now use a new set of specific billing codes, a change experts believe will streamline reimbursement and bolster patient access to this critical therapy.

The Centers for Medicare & Medicaid Services (CMS) has implemented three indication-specific Healthcare Common Procedure Coding System (HCPCS) codes for Tyenne when used to treat hospitalized COVID-19 patients. The new codes—Q0238 for injection, M0233 for the first intravenous dose, and M0234 for the second intravenous dose—became effective for claims on April 1, 2026. This development marks a pivotal moment in the ongoing management of the virus, replacing the uncertainty of miscellaneous codes with a clear, predictable pathway for reimbursement.

Streamlining Care in an Enduring Pandemic

For hospitals and clinics on the front lines, the establishment of dedicated HCPCS codes is more than a bureaucratic update; it's a fundamental operational improvement. Previously, billing for new drugs or new indications of existing drugs often required the use of generic or “not otherwise specified” codes. This practice frequently led to administrative delays, manual reviews, and uncertainty over payment amounts, creating a disincentive for providers and a potential barrier to care.

The new codes for Tyenne directly address this challenge. By providing a clear and standardized method for submitting claims, they are expected to facilitate faster and more reliable reimbursement. This financial predictability allows healthcare systems to more confidently manage their resources and ensure that treatments like Tyenne are readily available for patients who meet the clinical criteria.

“Fresenius Kabi’s indication-specific codes for COVID-19 represent an important step in supporting provider access and streamlined reimbursement for Tyenne,” said Molly Benson, senior vice president of Biopharma at Fresenius Kabi USA, in a recent statement. “Clear coding helps facilitate efficient claims processing and reinforces our commitment to ensuring patients have access to important treatment options.”

This move underscores the reality that COVID-19, while no longer a novel public health emergency, remains a persistent threat that requires a sophisticated and sustainable treatment infrastructure. For hospitalized patients experiencing severe inflammation, immunomodulatory drugs like Tyenne are a crucial part of the therapeutic arsenal.

The Growing Role of Biosimilars in Healthcare

The approval of these codes is also a significant milestone for the broader biosimilar market in the United States. Tyenne is a biosimilar to Actemra® (tocilizumab), a biologic drug that has been a key treatment for both autoimmune diseases and, more recently, severe COVID-19. A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.

Biosimilars are a critical component of the national strategy to control spiraling healthcare costs. By introducing market competition, they typically launch at a lower price point than their reference biologics, generating substantial savings for the healthcare system and for patients. The U.S. biosimilar market is projected to grow significantly, potentially saving the healthcare system over $180 billion in the next five years alone.

Legislative efforts, such as the Inflation Reduction Act, have further encouraged the adoption of biosimilars by providing enhanced Medicare Part B reimbursement for qualifying products. The establishment of clear coding for Tyenne's COVID-19 use aligns perfectly with this policy direction, removing friction from the system and making it easier for providers to choose the more cost-effective option. This development is seen by industry analysts as a case study in how biosimilar manufacturers can successfully navigate the complex U.S. reimbursement landscape to secure market access.

Clinical Context and Patient Impact

Tyenne’s role in COVID-19 treatment is highly specific and backed by clinical evidence. Leading health organizations, including the National Institutes of Health (NIH), recommend an IL-6 receptor antagonist like tocilizumab for certain hospitalized patients. Guidelines suggest its use for individuals who are already receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation, or ECMO due to progressive, severe disease marked by systemic inflammation.

For these critically ill patients, the impact of streamlined access cannot be overstated. When providers are confident in the reimbursement process, patients are less likely to face delays in receiving treatment. Furthermore, the lower cost of a biosimilar can translate into reduced out-of-pocket expenses for Medicare beneficiaries, who may otherwise face significant co-insurance or deductible payments for expensive biologic drugs.

While specific codes are a major step forward, some barriers may remain. Final access often depends on a hospital’s formulary decisions and individual Medicare plan structures. However, this move by CMS is widely seen as dismantling one of the most significant logistical obstacles, paving the way for broader and more equitable access to a life-saving therapy.

A Strategic Milestone for Fresenius Kabi

For Fresenius Kabi, a global healthcare company with a growing presence in biopharmaceuticals, securing these codes represents a key strategic victory. The company has made substantial investments in its U.S. manufacturing and distribution network, signaling a long-term commitment to the market. Tyenne is the company's third biosimilar launched in the U.S. and holds a unique competitive advantage as the first tocilizumab biosimilar approved with both intravenous and subcutaneous formulations, offering greater flexibility in treatment settings.

Achieving dedicated reimbursement codes for a complex indication like COVID-19 demonstrates the company's expertise in navigating the intricate regulatory and payment systems that govern advanced medicines. This success not only solidifies Tyenne's position in the COVID-19 treatment landscape but also strengthens Fresenius Kabi’s reputation as a key player in the expanding biosimilar space.

As the healthcare system continues to adapt to long-term COVID-19 management, the integration of effective and affordable treatments is paramount. The new coding for Tyenne is a critical piece of that puzzle, reflecting a maturation of the pandemic response where operational efficiency and sustainable cost-management are as important as clinical efficacy.